treatment group

treatment group

Statistics A group formed by making all possible combinations of 2 factors
References in periodicals archive ?
The placebo group had increased sleepiness at shift end, but the treatment group did not.
Sustained virologic responses were seen in 30% of those in the 24-week treatment group, in 52% of those in the 48-week treatment group, and in none of those in the control group.
Three to four months later, they found that 19 percent of patients in the treatment group and 46 percent of the control group showed signs of recurrence.
In addition, at shift end the placebo group's RT10 was worse than that of the caffeine/nap treatment group.
Two of 47 patients in the treatment group died, compared with 10 of 46 in the placebo group, and the combined frequency of death and need for additional antibiotics was 11% in the treatment group, compared with 57% in the placebo group.
Sustained virologic responses were seen in 30% of those in the 24 week treatment group, in 52% of those in the 48-week treatment group, and in none of those in the control group.
The relative bioavailability seen in this treatment group was approximately 20% higher than that obtained with the Evista[R] controls.
Those in the treatment group were told to visualize the scenarios for 5-20 minutes per day (JAMA 286[5]:537-45, 2001).
In the study, the percentage of patients in the BROVANA 15 mcg treatment group who achieved improvement in FEV1 that was greater than or equal to 10% from predose was 88.
It was terminated after a mean follow-up of 2 years when patients in the treatment group were found to have a 30% lower risk of death than patients in the placebo group.
Patients in the treatment group had a mean AHI reduction of 24% vs.
Interim data demonstrate that the overall median survival time (MST) favored the ONCONASE plus doxorubicin treatment group (12 months) over the doxorubicin group (10 months).

Full browser ?